Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.
The occurrence of circulating immune complexes was investigated in 467 serum samples from 230 leukemia patients using the [(125)I]Clq-binding test. There was an increased serum [(125)I]Clq-binding activity in 40% of patients with acute myeloid leukemia, 23% with acute lymphatic leukemia, 46% in blastic crisis of chronic myeloid leukemia, 12% with chronic lymphatic leukemia, and 13% with chronic myeloid leukemia. In 48 patients, serum was also tested for soluble immune complexes by the Raji cell radioassay; the correlation between results of the two tests was significant. The Clq-binding material had properties identical with those of immune complexes. It sedimented as 14-28s material on sucrose density gradient. It contained IgG which could be dissociated at acid pH. Its Clq-binding properties could be removed after passage through anti-IgG immuno-absorbant or after a mild reduction-alkylation treatment, but were not sensitive to deoxyribonuclease treatment. Circulating immune complexes were found most commonly during the blastic stage of leukemia.Remission took place in 75.4% of patients with no detectable circulating immune complexes at the onset of acute leukemia, but in only 32.7% of those with detected complexes during this period. Median survival times of the former group of patients were more than 18 mo in acute myeloid leukemia and acute lymphatic leukemia and more than 8(1/2) mo in blastic crisis of chronic myeloid leukemia. The corresponding median survival times in the latter patient group were 64, 135, and 90 days. These findings were unrelated to prognostic features already known.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000936:Antigen-Antibody Complex; D002460:Cell Line; D002648:Child; D003172:Complement C1 / Q000378:metabolism; D005260:Female; D006680:HLA Antigens; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007518:Isoantibodies / Q000032:analysis; D007938:Leukemia / Q000276:immunology* / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011379:Prognosis
D000936:Antigen-Antibody Complex; D003172:Complement C1; D006680:HLA Antigens; D007074:Immunoglobulin G; D007518:Isoantibodies
Int Arch Allergy Appl Immunol. 1955;7(2):103-10
13262900
J Biol Chem. 1961 May;236:1372-9
13767412
Clin Exp Immunol. 1976 Nov;26(2):189-95
136325
Lancet. 1974 Jun 29;1(7870):1318-20
4134298
Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372-5
5288389
J Exp Med. 1974 Oct 1;140(4):877-94
4139225
Cancer. 1974 Oct;34(4 Suppl):suppl:1446-51
4370857
Cancer Res. 1974 May;34(5):1179-81
4276372
Cancer. 1974 Oct;34(4 Suppl):suppl:1469-73
4609389
Intervirology. 1974;4(5):292-302
4377147
Proc Natl Acad Sci U S A. 1974 Mar;71(3):685-9
4595570
J Natl Cancer Inst. 1974 May;52(5):1435-44
4208711
Isr J Med Sci. 1971 Jan;7(1):111-31
5549279
J Natl Cancer Inst. 1973 Mar;50(3):633-44
4267705
Nat New Biol. 1972 Aug 9;238(84):185-6
4340574
Clin Exp Immunol. 1974 Oct;18(2):237-42
4283118
Nature. 1973 Jan 12;241(5385):95-100
4121144
J Clin Invest. 1974 Dec;54(6):1273-8
4140196
Int J Cancer. 1974 Jun 15;13(6):824-38
4136591
J Immunol Methods. 1972 Nov;2(1):25-34
4139208
Immunology. 1968 Mar;14(3):415-23
4170512
J Lab Clin Med. 1967 May;69(5):749-57
4164824
Clin Exp Immunol. 1969 Jan;4(1):65-82
4182356
Nature. 1974 Oct 18;251(5476):648-50
4153575
Science. 1974 Jan 11;183(4120):94-6
4148704
Nature. 1973 Nov 16;246(5429):146-8
4148474
Nature. 1968 Dec 28;220(5174):1352-4
4302696
Lancet. 1976 Feb 28;1(7957):449-51
55719
Lancet. 1976 Jun 5;1(7971):1249
58301
Int J Cancer. 1976 Sep 15;18(3):310-6
783053
J Immunol. 1974 Dec;113(6):1876-82
4214865
Transplant Rev. 1975;27:100-34
52924
N Engl J Med. 1973 Sep 6;289(10):520-2
4579334
Clin Exp Immunol. 1973 Jun;14(2):159-67
4577850
N Engl J Med. 1973 Jan 25;288(4):169-75
4565852
Immunology. 1975 Mar;28(3):535-42
47837
J Natl Cancer Inst. 1974 May;52(5):1529 36
4598556
N Y State J Med. 1973 May 15;73(10):1180-5
4512241
Int J Cancer. 1972 Mar 15;9(2):274-83
4504846
Science. 1974 Nov 1;186(4162):454-6
4413334
Cancer. 1974 Oct;34(4 Suppl):suppl:1452-60
4422494
J Clin Invest. 1976 Jan;57(1):169-82
128562
J Clin Invest. 1974 Jul;54(1):128-37
4857905
J Immunol. 1973 Mar;110(3):820-8
4734666
Cell Immunol. 1972 Mar;3(3):341-60
5013308
Immunochemistry. 1975 Apr;12(4):273-8
811545
J Clin Invest. 1975 Aug;56(2):331-8
807598
N Engl J Med. 1971 Nov;285(22):1211-6
5286519
Cancer Res. 1976 Jan;36(1):43-7
764968
J Natl Cancer Inst. 1975 Dec;55(6):1281-9
1107571
Clin Immunol Immunopathol. 1975 Sep;4(3):374-81
1104228
Clin Exp Immunol. 1976 Jan;23(1):83-90
1063068
Clin Exp Immunol. 1976 Jun;24(3):379-84
780020
Int J Cancer. 1975 Jun 15;15(6):995-9
1056897
J Immunol. 1976 Jan;116(1):232-5
1245740
Eur J Cancer. 1975 Jun;11(6):451-5
1172467
Clin Exp Immunol. 1971 Aug;9(2):193-9
5570677
Int J Cancer. 1971 Mar 15;7(2):226-37
5104167
Clin Exp Immunol. 1968 Nov;3(9):889-99
5751874